Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12610000565044
ACTRN12610000565044
Not yet recruiting
Phase 2

Pilot Clinical Trial for Treatment of Diabetic Foot Ulcers with Dietary Nano-formulated Phytochemicals in Mediterranean and Middle eastern Males suffering from Type 2 Diabetes with diabetic foot syndrome.

CamMedica, Ltd.0 sites35 target enrollmentJuly 13, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsdiabetic foot ulcersMetabolic and Endocrine - Diabetes

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
diabetic foot ulcers
Sponsor
CamMedica, Ltd.
Enrollment
35
Status
Not yet recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 13, 2010
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
CamMedica, Ltd.

Eligibility Criteria

Inclusion Criteria

  • •Mediterranean and Middle Eastern males, age 18\-65 (inclusive) suffering from Type 2 Diabetes with diabetic foot syndrome (1 and 2 grade Wagner scale) with body weight between 60\-80 kg.
  • •Stable metabolic and glycemic control during last three months of disease and during trial period.
  • •Foot ulcer aged at least two weeks sized 0\.5\-2\.0 cm.

Exclusion Criteria

  • •Any foot ulceration not related to type 2 diabetes
  • •Diabetic foot syndrome graded above 2 on Wagner's scale.
  • •Kidney abnormalities requiring medical intervention.
  • •Infectious complications of diabetic foot syndrome.
  • •Critical abnormalities of blood circulation in affected limb.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
DIAbetes-PREvention Trialpre-diabeticiHeart problemspre-diabetics10011082
NL-OMON38088Isala Klinieken78
Active, not recruiting
Not Applicable
Diabetes-Prevention TrialPatients who are candidates for cardiac rehabilitation after documented coronairy artery disease (PCI or CABG in stable CAD, or post STEMI and post non-STEMI), who have pre-diabetesMedDRA version: 14.1Level: LLTClassification code 10064346Term: STEMISystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10036482Term: Pre-diabeticSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-002469-39-NLIsala Klinieken
Completed
Not Applicable
Early Diabetes Intervention TrialImpaired glucose toleranceNutritional, Metabolic, EndocrineDiabetes
ISRCTN96631607Bayer plc and Merck-Lipha (UK)631
Active, not recruiting
Phase 1
Ensayo clínico de tratamiento de la Diabetes Mellitus tipo 1 autoinmune con células madre mesenquimales autólogas
EUCTR2009-017228-24-ESInstituto Científico y Tecnológico de Navarra15
Active, not recruiting
Not Applicable
Testing a non-invasive smartphone application to predict sugar levels in the blood
ISRCTN15977623Bioepic Ltd72